# A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

> **NCT01286818** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 6 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **BIOLOGICAL:** Ramucirumab (IMC-1121B)
- **DRUG:** Irinotecan
- **DRUG:** levofolinate
- **DRUG:** 5-Fluorouracil (5-FU)

## Key facts

- **NCT ID:** NCT01286818
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-02
- **Final completion:** 2012-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01286818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01286818, "A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01286818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*